JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Development and validation of a nomogram for local control prediction in lung cancer patients treated with stereotactic body radiation therapy based on clinical, dosimetric, and inflammation-related parameters

  • 0Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China. hbt830910@126.com.
Bmc Pulmonary Medicine +

|

July 9, 2025

|

July 9, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies key risk factors for local recurrence in lung cancer patients after stereotactic body radiation therapy (SBRT). A new nomogram predicts local control (LC) to improve patient outcomes.

Area Of Science

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background

  • Local recurrence is a significant concern for lung cancer patients undergoing stereotactic body radiation therapy (SBRT).
  • Predictive models are needed to identify patients at higher risk for local recurrence.
  • Understanding risk factors is crucial for optimizing SBRT treatment strategies.

Purpose Of The Study

  • To identify independent risk factors associated with local control (LC) in lung cancer patients treated with SBRT.
  • To develop and validate a predictive nomogram for LC in this patient population.
  • To enhance the precision of treatment planning and patient stratification.

Main Methods

  • Retrospective analysis of 158 lung cancer patients treated with SBRT.
  • Collection of clinical, dosimetric, and inflammation-related parameters.
  • Multivariate Cox regression analysis to identify prognostic factors and development of a nomogram, internally validated using bootstrap resampling.

Main Results

  • The study found a local recurrence rate of 35.4% with median follow-up of 40 months.
  • Six independent factors (age, clinical stage, PTV volume, BEDPD, lymphocyte count, neutrocyte count) were associated with LC.
  • The developed nomogram demonstrated strong discriminatory capability (C-index 0.745) and clinical utility.

Conclusions

  • A nomogram integrating clinical, dosimetric, and inflammation-related factors can predict local control in lung cancer patients treated with SBRT.
  • The nomogram shows potential for stratifying patients into high- and low-risk groups.
  • Further external validation is recommended to confirm the nomogram's robustness.

Keywords: